Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
Abstract Background To study the clinical outcomes of pigment epithelial detachment (PED) associated with neovascular age-related macular degeneration (nAMD) in patients switched from Ranibizumab to Aflibercept. Methods Retrospective non-comparative case series. 50 eyes with active nAMD and fovea in...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-06-01
|
| Series: | BMC Ophthalmology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12886-018-0824-0 |
| _version_ | 1818038523841740800 |
|---|---|
| author | Pallavi Tyagi Zain Juma Yong Keen Hor Neil W. Scott Andreea Ionean Cynthia Santiago |
| author_facet | Pallavi Tyagi Zain Juma Yong Keen Hor Neil W. Scott Andreea Ionean Cynthia Santiago |
| author_sort | Pallavi Tyagi |
| collection | DOAJ |
| description | Abstract Background To study the clinical outcomes of pigment epithelial detachment (PED) associated with neovascular age-related macular degeneration (nAMD) in patients switched from Ranibizumab to Aflibercept. Methods Retrospective non-comparative case series. 50 eyes with active nAMD and fovea involving PED of ≥100 μm measured manually using the caliper on the OCT, initially treated with intravitreal Ranibizumab (0.5 mg/0.05 ml) and later switched to Aflibercept (2.0 mg/0.05 ml). The outcome measures of best corrected visual acuity (BCVA), PED height, PED width and number of injections were measured at baseline and at time point of switch, 4 months, 1 year and at last follow up visit post-switch. Three paired t-tests and Pearson’s correlations were calculated to analyze variables at switch and change in variables at 1 year. Results After switch to Aflibercept, the improvement of BCVA was 1.84 (p = 0.11), 1.74 (p = 0.21) and 1.16 (p = 0.45) letters, the change in PED height was − 65.6μm (p < 0.001), − 50.64μm (p = 0.007) and − 68.48μm (p < 0.001) and the change in PED width was − 36.6μm (p = 0.514), + 29.7μm (p = 0.922) and + 118.4μm (p = 0.210) at 4 months, 1 year and the last visit respectively. There was a moderate negative correlation between reduction in PED height at 1 year after switch and PED height at the time of switch to Aflibercept (r = − 0.474, p < 0.05). Conclusion The improvement in BCVA and change in PED width was not statistically significant however the reduction in PED height was significant after switching treatment to Aflibercept. The change in BCVA at 1 year after switch was not correlated with any of the analyzed anatomical characteristics of PED. |
| first_indexed | 2024-12-10T07:44:06Z |
| format | Article |
| id | doaj.art-ebc4741ace514ee1a6d941b610514b31 |
| institution | Directory Open Access Journal |
| issn | 1471-2415 |
| language | English |
| last_indexed | 2024-12-10T07:44:06Z |
| publishDate | 2018-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Ophthalmology |
| spelling | doaj.art-ebc4741ace514ee1a6d941b610514b312022-12-22T01:57:14ZengBMCBMC Ophthalmology1471-24152018-06-011811810.1186/s12886-018-0824-0Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to AfliberceptPallavi Tyagi0Zain Juma1Yong Keen Hor2Neil W. Scott3Andreea Ionean4Cynthia Santiago5Department of Ophthalmology, Aberdeen Royal infirmaryDepartment of Ophthalmology, Aberdeen Royal infirmaryThe school of medicine, University of AberdeenMedical Statistics Team, University of AberdeenDepartment of Ophthalmology, Aberdeen Royal infirmaryDepartment of Ophthalmology, Aberdeen Royal infirmaryAbstract Background To study the clinical outcomes of pigment epithelial detachment (PED) associated with neovascular age-related macular degeneration (nAMD) in patients switched from Ranibizumab to Aflibercept. Methods Retrospective non-comparative case series. 50 eyes with active nAMD and fovea involving PED of ≥100 μm measured manually using the caliper on the OCT, initially treated with intravitreal Ranibizumab (0.5 mg/0.05 ml) and later switched to Aflibercept (2.0 mg/0.05 ml). The outcome measures of best corrected visual acuity (BCVA), PED height, PED width and number of injections were measured at baseline and at time point of switch, 4 months, 1 year and at last follow up visit post-switch. Three paired t-tests and Pearson’s correlations were calculated to analyze variables at switch and change in variables at 1 year. Results After switch to Aflibercept, the improvement of BCVA was 1.84 (p = 0.11), 1.74 (p = 0.21) and 1.16 (p = 0.45) letters, the change in PED height was − 65.6μm (p < 0.001), − 50.64μm (p = 0.007) and − 68.48μm (p < 0.001) and the change in PED width was − 36.6μm (p = 0.514), + 29.7μm (p = 0.922) and + 118.4μm (p = 0.210) at 4 months, 1 year and the last visit respectively. There was a moderate negative correlation between reduction in PED height at 1 year after switch and PED height at the time of switch to Aflibercept (r = − 0.474, p < 0.05). Conclusion The improvement in BCVA and change in PED width was not statistically significant however the reduction in PED height was significant after switching treatment to Aflibercept. The change in BCVA at 1 year after switch was not correlated with any of the analyzed anatomical characteristics of PED.http://link.springer.com/article/10.1186/s12886-018-0824-0AfliberceptPigment epithelial detachmentNeovascular age related macular degeneration |
| spellingShingle | Pallavi Tyagi Zain Juma Yong Keen Hor Neil W. Scott Andreea Ionean Cynthia Santiago Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept BMC Ophthalmology Aflibercept Pigment epithelial detachment Neovascular age related macular degeneration |
| title | Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept |
| title_full | Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept |
| title_fullStr | Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept |
| title_full_unstemmed | Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept |
| title_short | Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept |
| title_sort | clinical response of pigment epithelial detachment associated with neovascular age related macular degeneration in switching treatment from ranibizumab to aflibercept |
| topic | Aflibercept Pigment epithelial detachment Neovascular age related macular degeneration |
| url | http://link.springer.com/article/10.1186/s12886-018-0824-0 |
| work_keys_str_mv | AT pallavityagi clinicalresponseofpigmentepithelialdetachmentassociatedwithneovascularagerelatedmaculardegenerationinswitchingtreatmentfromranibizumabtoaflibercept AT zainjuma clinicalresponseofpigmentepithelialdetachmentassociatedwithneovascularagerelatedmaculardegenerationinswitchingtreatmentfromranibizumabtoaflibercept AT yongkeenhor clinicalresponseofpigmentepithelialdetachmentassociatedwithneovascularagerelatedmaculardegenerationinswitchingtreatmentfromranibizumabtoaflibercept AT neilwscott clinicalresponseofpigmentepithelialdetachmentassociatedwithneovascularagerelatedmaculardegenerationinswitchingtreatmentfromranibizumabtoaflibercept AT andreeaionean clinicalresponseofpigmentepithelialdetachmentassociatedwithneovascularagerelatedmaculardegenerationinswitchingtreatmentfromranibizumabtoaflibercept AT cynthiasantiago clinicalresponseofpigmentepithelialdetachmentassociatedwithneovascularagerelatedmaculardegenerationinswitchingtreatmentfromranibizumabtoaflibercept |